{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:23:43Z","timestamp":1782271423657,"version":"3.54.5"},"reference-count":19,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2022,6,22]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Pathological laughter and crying is a disabling symptom complex associated with damage to various central nervous system pathways that control the reflex motor component of emotional expression. Many underlying conditions\u2014including neurodegenerative diseases, CNS inflammation, vascular lesions and traumatic brain injury\u2014can be associated with disinhibition of emotional reflex control. This suggests a disruption of anatomical and functional networks, rather than any specific unifying pathological process. There is a wide differential diagnosis, including depression, dementia and other forms of behavioural disturbance. Diagnostic criteria and rating scales can help with clinical assessments and facilitate clinical trials. There is now good-quality evidence for a combination of dextromethorphan and quinidine, with weaker evidence for tricyclic and selective serotonin reuptake inhibitor antidepressants. Pathological laughter and crying is disabling and underdiagnosed but potentially treatable, and its wider recognition is important.<\/jats:p>","DOI":"10.1136\/pn-2021-003301","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T13:20:17Z","timestamp":1659187217000},"page":"486-490","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Pathological laughter and crying in neurological disorders: recognition and treatment"],"prefix":"10.1136","volume":"22","author":[{"given":"Emma","family":"Husbands","sequence":"first","affiliation":[{"name":"Palliative Medicine, GHNHSFT, Gloucester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Talbot","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"2025090410340843000_22.6.486.1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.17925\/ENR.2013.08.02.74","article-title":"Pseudobulbar affect\u2014a disabling but under-recognised consequence of neurological disease and brain injury","volume":"8","author":"Andersen","year":"2013","journal-title":"Europ Neurol Rev"},{"key":"2025090410340843000_22.6.486.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900026614","article-title":"Defining and diagnosing involuntary emotional expression disorder","volume":"11","author":"Cummings","year":"2006","journal-title":"CNS Spectr"},{"key":"2025090410340843000_22.6.486.3","first-page":"39","article-title":"Pathological laughing and crying","volume":"16","author":"Wilson","year":"1923","journal-title":"Proc R Soc Med"},{"key":"2025090410340843000_22.6.486.4","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/ern.11.68","article-title":"Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments","volume":"11","author":"Miller","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"2025090410340843000_22.6.486.5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.9.1708"},{"key":"2025090410340843000_22.6.486.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cortex.2009.11.008"},{"key":"2025090410340843000_22.6.486.7","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1212\/WNL.0000000000000693","article-title":"Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders","volume":"83","author":"Floeter","year":"2014","journal-title":"Neurology"},{"key":"2025090410340843000_22.6.486.8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s12325-012-0043-7","article-title":"Pseudobulbar affect: burden of illness in the USA","volume":"29","author":"Colamonico","year":"2012","journal-title":"Adv Ther"},{"key":"2025090410340843000_22.6.486.9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12325-011-0031-3","article-title":"Pseudobulbar affect: an under-recognized and under-treated neurological disorder","volume":"28","author":"Work","year":"2011","journal-title":"Adv Ther"},{"key":"2025090410340843000_22.6.486.10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1177\/2374373519899597","article-title":"Living with the burden of pseudobulbar affect: a qualitative analysis of the effects of education on patient experience","volume":"7","author":"Turell","year":"2020","journal-title":"J Patient Exp"},{"key":"2025090410340843000_22.6.486.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20828"},{"key":"2025090410340843000_22.6.486.12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22093"},{"key":"2025090410340843000_22.6.486.13","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000142042.50528.2F"},{"key":"2025090410340843000_22.6.486.14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12883-016-0609-0","article-title":"Prism II: an open-label study to assess effectiveness of dextromethorphan\/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury","volume":"16","author":"Hammond","year":"2016","journal-title":"BMC Neurol"},{"key":"2025090410340843000_22.6.486.15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1185\/03007995.2014.940040","article-title":"An open-label multicenter study to assess the safety of dextromethorphan\/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions","volume":"30","author":"Pattee","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025090410340843000_22.6.486.16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1089\/jpm.2016.0277","article-title":"Use of compounded Dextromethorphan-Quinidine suspension for pseudobulbar affect in hospice patients","volume":"20","author":"Wahler","year":"2017","journal-title":"J Palliat Med"},{"key":"2025090410340843000_22.6.486.17","article-title":"Pharmaceutical interventions for emotionalism after stroke","volume":"3","author":"Allida","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090410340843000_22.6.486.18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/21678421.2019.1674874","article-title":"The clinical impact of the Edinburgh cognitive and behavioural ALS screen (ECAS) and neuropsychological intervention in routine ALS care","volume":"21","author":"Hodgins","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2025090410340843000_22.6.486.19","unstructured":"Gmc-uk.org . Ethical guidance, 2022. Available: https:\/\/www.gmc-uk.org\/ethical-guidance\/ethical-guidance-for-doctors [Accessed 11 Mar 2022]."}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2021-003301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:34:22Z","timestamp":1757007262000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2021-003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,30]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/pn-2021-003301"],"URL":"https:\/\/doi.org\/10.1136\/pn-2021-003301","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}